U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 10-QSB


    [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                                   ACT OF 1934

                 For the quarterly period ended: March 31, 2005

       [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                           Commission File No. 0-11808

                             MB SOFTWARE CORPORATION


             Texas                                               59-2220004
(State or other jurisdiction of                              (I.R.S. Employer
 incorporation or organization)                           Identification Number)

                      2225 E. Randol Mill Road - Suite 305
                           Arlington, Texas 76011-6306
                                 (817) 633-9400


Check  whether the Issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or
for shorter period that the  registrant was required to file such reports),  and
(2) has been subject to such filing requirements for the past 90 days.
                                    Yes  [X]                No  [ ]


As of March 31, 2005,  14,921,432  of the Issuer's  $.001 par value common stock
were outstanding.

Transitional Small Business Disclosure Format
                                    Yes  [ ]                No  [X]

<PAGE>

                    MB SOFTWARE CORPORATION AND SUBSIDIARIES

                                   Form 10-QSB

                          Quarter Ended March 31, 20045


PART I - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

Consolidated Balance Sheet as of March 31, 2005 (Unaudited)....................3

Consolidated Statements of Operations for the three months ended
        March 31, 2005and 2004 (Unaudited).....................................4

Consolidated Statements of Cash Flows for the three months ended
        March 31, 2005 and 2004 (Unaudited)....................................5


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS.............8

ITEM 3. CONTROLS AND PROCEDURES...............................................11

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings.....................................................12
ITEM 2. Changes in Securities and Use of Proceeds.............................12
ITEM 3. Defaults Upon Senior Securities.......................................12
ITEM 4. Submission of Matters to a Vote of Security Holders...................12
ITEM 5. Other Information.....................................................12
ITEM 6. Exhibits..............................................................12

SIGNATURE.....................................................................12





                                       2
<PAGE>
<TABLE>
<CAPTION>

PART I - FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS

                    MB SOFTWARE CORPORATION AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEET
                                 MARCH 31, 2005
                                   (UNAUDITED)
--------------------------------------------------------------------------------
ASSETS
------
<S>                                                                  <C>
Current Assets
   Cash                                                              $      2,781
   Accounts receivable                                                     23,930
   Inventory                                                               90,030
   Prepayments                                                            112,512
                                                                     ------------
Total current assets                                                      229,253

Fixed assets, net                                                          79,063
Other assets - patents                                                     75,000
Security deposits                                                          15,693
                                                                     ------------

Total Assets                                                         $    399,009
                                                                     ============

LIABILITIES AND STOCKHOLDERS' DEFICIENCY
----------------------------------------
Current liabilities
   Accounts payable and other accruals                               $    132,574
   Payroll tax liabilities                                                 84,445
   Obligation under capital lease - current portion                         4,092
   Due to related parties                                                 309,601
                                                                     ------------
Total current liabilities                                                 530,712

Long-term liabilities
   Obligation under capital lease - noncurrent portion                      5,217
                                                                     ------------

Total Liabilities                                                         535,929

Stockholders' Deficiency
   Preferred stock, $10 par value, 5,000,000 shares authorized;
      issued and outstanding none                                            --
   Common stock:  $0.001 par value;  20,000,000 shares authorized;
      issued and outstanding: 14,921,432                                   14,921
   Stock subscription                                                     221,971
   Additional paid-in capital                                          15,159,637
   Accumulated deficit                                                (15,521,410)
                                                                     ------------
                                                                         (124,881)
   Less: treasury stock, at cost;  4,089 shares                           (12,039)
                                                                     ------------
Total stockholders' deficiency                                           (136,920)
                                                                     ------------

Total Liabilities and Stockholders' Deficiency                       $    399,009
                                                                     ============
</TABLE>

            See condensed notes to consolidated financial statements.


                                       3
<PAGE>

                    MB SOFTWARE CORPORATION AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                       FOR THE THREE MONTHS ENDED MARCH 31
                                   (UNAUDITED)

--------------------------------------------------------------------------------

                                                 2005            2004
                                             ------------    ------------
Revenues                                     $     56,261    $       --
Cost of revenues                                   53,363            --
                                             ------------    ------------
Gross margin                                        2,898            --

Selling, general and administrative               172,497          25,495
                                             ------------    ------------

Loss from operations                             (169,599)        (25,495)

Other income (expense), net                        (7,406)           --
                                             ------------    ------------

Loss before provision for income taxes           (177,005)        (25,495)

Provision for income taxes                           --              --
                                             ------------    ------------

Loss from continuing operations                  (177,005)        (25,495)

Discontinued operations
   Operating loss                                    --           (60,653)
                                             ------------    ------------

Net loss                                     $   (177,005)   $    (86,148)
                                             ============    ============



Basic and diluted loss per share:
   Continuing operations                     $      (0.01)   $       --
   Discontinued operations                           --             (0.01)
                                             ------------    ------------
                                             $      (0.01)   $      (0.01)
                                             ============    ============

Weighted average common shares outstanding     14,921,432       5,822,810
                                             ============    ============




            See condensed notes to consolidated financial statements.


                                       4
<PAGE>
<TABLE>
<CAPTION>

                    MB SOFTWARE CORPORATION AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                       FOR THE THREE MONTHS ENDED MARCH 31
                                   (UNAUDITED)

--------------------------------------------------------------------------------

                                                                                    2005         2004
                                                                                  ---------    ---------
<S>                                                                               <C>          <C>
Cash flows from operatwing activities
-------------------------------------
Net loss                                                                          $(177,005)   $ (86,148)
Adjustments to reconcile net loss from to net cash used in operating activities
   Depreciation and amortization                                                      2,002        5,000
Changes in assets and liabilities:
   (Increase) decrease in accounts receivable                                        (3,844)        --
   (Increase) decrease in inventory                                                   5,270         --
   (Increase) decrease in prepaid expenses and other assets                        (112,512)      (1,588)
    Increase (decrease) in accounts payable and accrued liabilities                  65,123       28,174
                                                                                  ---------    ---------
Net cash flows used in operating activities                                        (220,966)     (54,562)

Cash flows from investing activities
------------------------------------
   Cash paid for intangible assets                                                  (75,000)     (50,000)
   Purchase of fixed assets                                                         (26,144)     (13,626)
                                                                                  ---------    ---------
Net cash flows used in investing activities                                        (101,144)     (63,626)

Cash flows from financing activities
------------------------------------
   Cash overdraft                                                                      --          1,049
   Proceeds from new borrowings                                                        --         25,000
   Net advances - related parties                                                   318,025       91,754
   Principal payments under capital lease                                            (1,023)        --
                                                                                  ---------    ---------
Net cash flows provided by financing activities                                     317,002      117,803
                                                                                  ---------    ---------

Increase (decrease) in cash                                                          (5,108)        (385)

Cash and cash equivalents, beginning of period                                        7,889          385
                                                                                  ---------    ---------

Cash and cash equivalents, end of period                                          $   2,781    $    --
                                                                                  =========    =========

Cash paid during the year for:
------------------------------
   Interest                                                                            --      $  13,354
                                                                                  =========    =========
   Income taxes                                                                        --           --
                                                                                  =========    =========
</TABLE>



            See condensed notes to consolidated financial statements.





                                       5
<PAGE>

                    MB SOFTWARE CORPORATION AND SUBSIDIARIES
                          QUARTER ENDED MARCH 31, 2005
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

--------------------------------------------------------------------------------

NOTE 1: BASIS OF PRESENTATION

The accompanying  unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles in the United States
of America for interim  financial  information and with the instructions to Form
10-QSB and Rule 10-01 of Regulation S-X. They do not include all information and
notes required by generally accepted accounting  principles in the United States
of America for complete financial statements.

In the  opinion of  management,  all  adjustments  (which  include  only  normal
recurring  adjustments)  necessary  to present  fairly the  financial  position,
results of operations  and cash flows for all periods  presented have been made.
Preparing  financial  statements  requires  management  to  make  estimates  and
assumptions that affect the reported amounts of assets, liabilities, revenue and
expenses.  Actual  results  may differ  from  these  estimates.  The  results of
operations for the period ended March 31, 2005 are not necessarily indicative of
the operating  results that may be expected for the entire year ending  December
31, 2005.  These  financial  statements  should be read in conjunction  with the
Management's  Discussion  and  Analysis  included  in  the  Company's  financial
statements and accompanying  notes thereto as of and for the year ended December
31, 2004, filed with the Company's Annual Report on Form 10-KSB

Certain  financial  information  for the prior period has been  reclassified  to
conform to the current period's presentation.


NOTE 2: GOING CONCERN

The financial  statements  have been prepared on a going  concern  basis,  which
contemplates  realization  of  assets  and  liquidation  of  liabilities  in the
ordinary course of business.  The Company has continuously  incurred losses from
operations and has a significant  accumulated  deficit.  The  appropriateness of
using the going concern basis is dependent upon the Company's  ability to obtain
additional  financing or equity capital and,  ultimately,  to achieve profitable
operations.  These  conditions  raise  substantial  doubt  about its  ability to
continue as a going concern.

It is the  Company's  belief that it will  continue to incur losses for at least
the next twelve months,  and as a result will require additional funds from debt
or equity investments to meet such needs. To meet these objectives, management's
plans are to (i) raise capital by obtaining  financing from debt financing and /
or equity financing through private placement  efforts,  (ii) issue common stock
for  services  rendered in lieu of cash  payments  and (iii)  obtain  loans from
shareholders  as  necessary.   Without  realization  of  additional  capital  or
significant  revenues from  operations,  it would be unlikely for the Company to
continue as a going concern.  The Company anticipates that its shareholders will
contribute  sufficient  funds to satisfy  the cash needs of the  Company for the
next twelve months.  However,  there can be no assurances to that effect, as the
Company  has  minimal  revenues  and the  Company's  need for capital may change
dramatically if it is successful in expanding its current  business or acquiring
a new business.  If the Company cannot obtain needed funds,  it may be forced to
curtail or cease its activities.

Management  believes  that  actions  presently  taken to  revise  the  Company's
operating and financial  requirements provide the opportunity for the Company to
continue as a going  concern.  The  Company's  future  ability to achieve  these
objectives  cannot  be  determined  at this  time.  The  accompanying  financial
statements do not include any adjustments  that might result from the outcome of
this uncertainty.


                                       6
<PAGE>

NOTE 3: RELATED PARTY TRANSACTIONS

Due to related parties represent funds advanced from various entities controlled
by the president of this Company, and other majority shareholders, as necessary,
to meet working  capital  requirements.  The advances  bear  interest at 10% per
annum, are unsecured and repayable on demand.


NOTE 4:  OTHER ASSETS - PATENTS

Other assets represent cash amounts paid by the Company to maintain its right to
acquire  certain  patents related to the hydrolyzed Type I form of collagen used
within gel,  powder,  paste and film collagen would dressing  compositions.  The
total cash  exercise  price of the patent and related  intellectual  property is
$5,100,000 and the Company pays $75,000 per year as an option fee to to maintain
its rights to purchase the said property.


NOTE 5: DISCONTINUED OPERATIONS

The Company  disposed of its  wholly-owned  subsidiary,  MB Holding  Corporation
("MBH") in December  2004.  MBH,  through  its  wholly-owned  subsidiary  Envoii
Healthcare L.L.C., developed a system for transmitting electronic documents in a
secure environment.

Condensed  results of  operations  included in  discontinued  operations  are as
follows:

Revenues                                   $    10,717
Expenses                                       (71,370)
                                           -----------
Operating loss                             $    60,653
                                           ===========












                                       7
<PAGE>

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS/RISK FACTORS

The  following  discussion  should  be read in  conjunction  with the  Company's
financial  statements and the notes thereto and the other financial  information
appearing elsewhere in this document. In addition to historical information, the
following   discussion  and  other  parts  of  this  document   contain  certain
forward-looking information. When used in this discussion, the words "believes,"
"anticipates,"  "expects,"  and  similar  expressions  are  intended to identify
forward-looking  statements.  Such  statements  are subject to certain risks and
uncertainties,  which could cause actual results to differ materially from those
projected  due to a number of factors  beyond our control.  The Company does not
undertake  to publicly  update or revise any of its  forward-looking  statements
even if experience or future  changes show that the indicated  results or events
will not be realized.  You are  cautioned  not to place undue  reliance on these
forward-looking statements, which speak only as of the date hereof. You are also
urged to carefully  review and consider our  discussions  regarding  the various
factors,  which affect our  business,  included in this section and elsewhere in
this report.

Factors that might cause actual  results,  performance or achievements to differ
materially  from those projected or implied in such  forward-looking  statements
include,  among  other  things:  (i) the impact of  competitive  products;  (ii)
changes in law and  regulations;  (iii) adequacy and  availability  of insurance
coverage;  (iv)  limitations on future  financing;  (v) increases in the cost of
borrowings  and  unavailability  of debt or equity  capital;  (vi) the effect of
adverse publicity regarding our products;  (vii) the inability of the Company to
gain and/or hold market share;  (viii)  exposure to and expense of resolving and
defending  product   liability  claims  and  other  litigation;   (ix)  consumer
acceptance of the Company's products;  (x) managing and maintaining growth; (xi)
customer  demands;  (xii) market and industry  conditions  including pricing and
demand for products,  (xiii) the success of product  development and new product
introductions  into the  marketplace;  (xiv) the  departure  of key  members  of
management;  (xv) the ability of the Company to efficiently market its products;
as well as other risks and  uncertainties  that are described  elsewhere in this
report and from time to time in the Company's  filings with the  Securities  and
Exchange Commission.


RISK FACTORS

We have sought to identify what we believe to be the most  significant  risks to
our business. However, we cannot predict whether, or to what extent, any of such
risks may be realized nor can we guarantee that we have  identified all possible
risks that might arise.  Investors  should  carefully  consider all of such risk
factors  before making an investment  decision with respect to our Common Stock.
We provide the  following  cautionary  discussion  of risks,  uncertainties  and
possible inaccurate assumptions relevant to our business. These are factors that
we think  could  cause our actual  results to differ  materially  from  expected
results. Other factors besides those listed here could affect us.

Lack of Operating History
-------------------------

We  acquired  Wound Care in August of 2004 and we have only a limited  operating
history with which you can evaluate our current business model and our prospects
and the  historical  financial  data may be of limited value in  evaluating  our
future revenue and operating expenses.  Further, you may lose your investment if
we are unable to  successfully  market our services and  implement  our business
plan. We have not been profitable to date.  Even if we become  profitable in the
future,  we cannot  accurately  predict  the level of, or our ability to sustain
profitability.  Because we have not yet been  profitable  and cannot predict any
level of  future  profitability,  you bear the risk of a  complete  loss of your
investment in the event our business plan is unsuccessful.


                                       8
<PAGE>

Inability to Obtain Funding
---------------------------

We may not be able to obtain additional  funding when needed,  which could limit
future  expansion and marketing  opportunities,  as well as result in lower than
anticipated   revenues.   We  may  require   additional   financing   to  pursue
relationships  with other  business  opportunities.  If the market  price of the
common stock declines,  some potential  financiers may either refuse to offer us
any  financing or will offer  financing  at  unacceptable  rates or  unfavorable
terms. If we are unable to obtain  financing on favorable terms, or at all, this
unavailability  could  prevent  us from  expanding  our  business,  which  could
materially impact our future potential revenues.

Sole Source of Products
-----------------------

Applied  Nutritionals  holds the patent to, and is currently  the sole source of
our  products.  In the event  Applied  Nutritionals  was not able to fulfill our
product  orders,  we would be prevented  from marketing and selling our products
into the market and we would be unable to conduct business.


OVERVIEW
--------


The  Company  currently  has limited  business  operations,  maintaining  leased
offices in Arlington,  Texas, and Fort Lauderdale  Florida.  Business activities
currently  include  sales and  marketing  activities  of our wound care products
through   certain   exclusive   and   nonexclusive    distribution   rights   of
CellerateRX(TM)  products.  The product is a  collagen-based  wound care product
line based upon a patented molecular form of collagen. Wound Care's distribution
rights  for these  products  are  exclusive  in the  domestic  medical,  retail,
government  and first aid human use would  care  markets,  as well as in several
international  markets.  Our  products  are FDA  cleared for  marketing  for the
following indications: Pressure ulcers, diabetic ulcers, surgical wounds, ulcers
due to arterial  insufficiency,  traumatic wounds, 1st and 2nd degree burns, and
superficial  wounds.  We believe that our  products  are unique in  composition,
applicability, clinical performance, and demonstrate the ability to reduce costs
associated with standard wound management.

          THREE MONTHS ENDED MARCH 31, 2005 COMPARED TO MARCH 31, 2004
          ------------------------------------------------------------

Results of Operations
---------------------

Revenues,  Cost of Sales and Gross  Margin.  The Company  generated  revenues of
approximately  $56,000 for the three months  ended March 31,  2005,  through its
wholly-owned subsidiary Wound Care Innovations,  LLC, ("WCI"), which it acquired
in  August  2004.  Costs of sales  approximated  $53,000  and ross  margin  as a
percentage of sales  approximated  5%, which  approximates  the historical gross
margin since the Company's  acquisition  of WCI.  There were no revenues for the
same period in 2004. (See discontinued operations caption.)

Selling,  general and administrative  expenses ("SGA"). SGA for the three months
ended  March 31,  2005  approximated  $172,500  compared to $25,500 for the same
period in 2004, an increase of $147,000.  Approximately $132,500 of the increase
in expenses is comprised of WCI's  operations.  Major  contributors to WCI's SGA
expenses are (approximations)  wages of $75,000 for 3 employees in Florida, rent
of $17,000,  and legal fees of $7,000.  Major expenses related to the registrant
were  rent  fort  the  Company's   Arlington,   Texas  offices  of  $11,000  and
professional   fees  paid  in  connection   with  the  company's  SEC  reporting
requirements  of  $15,000.  SGA for the three  months  ended March 31, 2004 were
mainly comprised of professional  fees paid in connection with the company's SEC
reporting requirements and other corporate matters amounting to $23,000

Discontinued Operations. The Company disposed of its wholly-owned subsidiary, MB
Holding  Corporation  ("MBH") in December 2004.  MBH,  through its  wholly-owned
subsidiary  Envoii  Healthcare  L.L.C.,  developed  a  system  for  transmitting
electronic   documents  in  a  secure  environment.   Included  in  discontinued
operations for the three months ended March 31, 2004 was revenues of $10,717 and
expenses of $71,370.


                                       9
<PAGE>

Liquidity and Capital Resources
-------------------------------

The Company currently has limited resources to maintain its current  operations,
secure more inventory, and meet its contractual obligations.  Additional capital
must be raised immediately through equity or debt offerings. If we are unable to
obtain  additional  capital,  we will be unable to  operate  our  business.  The
Company has  continuously  incurred losses from operations and has a significant
accumulated  deficit.  The  appropriateness  of using the going concern basis is
dependent upon the Company's  ability to obtain  additional  financing or equity
capital and,  ultimately,  to achieve  profitable  operations.  These conditions
raise  substantial  doubt about its ability to continue as a going concern.  The
financial  statements do not include any adjustments  that might result from the
outcome of this uncertainty.

The Company also has minimal  revenues and a negative  cash flow from  operating
activities.  The Company  currently relies on its majority  shareholders to fund
operating  expenses  as  necessary.  It is the  Company's  belief  that  it will
continue to incur  losses for at least the next twelve  months,  and as a result
will  require  additional  funds  from debt or equity  investments  to meet such
needs. To meet these objectives,  management's plans are to (i) raise capital by
obtaining  financing  from  debt  financing  and / or equity  financing  through
private placement efforts, (ii) issue common stock for services rendered in lieu
of cash payments and (iii) obtain loans from shareholders as necessary.

Without   realization  of  additional  capital  or  significant   revenues  from
operations, it would be unlikely for the Company to continue as a going concern.
The  Company   anticipates  that  its  majority   shareholders  will  contribute
sufficient  funds to satisfy  the cash needs of the  Company for the next twelve
months.  However,  there can be no assurances to that effect, as the Company has
minimal  revenues and the Company's need for capital may change  dramatically if
it is successful in expanding its current  business or acquiring a new business.
If the Company cannot obtain needed funds,  it may be forced to curtail or cease
its activities. Our future funding requirements will depend on numerous factors,
some of which are  beyond the  Company's  control.  These  factors  include  our
ability to operate profitably,  recruit and train management and personnel,  and
to compete with other, better-capitalized and more established competitors.

The Company does not anticipate  incurring  significant research and development
costs,  the purchase of any major equipment,  or any significant  changes in the
number of its employees over the next twelve months.


Plan of Operation
-----------------

The  Company's  general  business plan is to introduce  CellerateRX  products to
select national and regional  healthcare  provider  organizations,  and focus on
geographically-targeted  marketing.  Our  products are  currently  being used by
providers  of all  types,  and are  getting  to  market  through  a  variety  of
distribution  channels.  Our products are currently  approved for  reimbursement
under Medicare Part B. As a consequence, the professional medical market is, and
will  remain  the  primary  focus of our  marketing  and sales  efforts  for the
immediate future.

The Company  does not  presently  generate  profits  and  expends  approximately
$59,000.00 to  $65,000.00  per month for working  capital and general  corporate
purposes, including any marketing expenses.

Products

CellerateRX  Gel and Powder are our two primary  products  for the  professional
healthcare  market.  Both products contain the patented form of collagen and can
be used on a variety of wounds,  wound states,  and phases.  We believe that the
spectrum  of use  of our  products  allows  us to  market  to a  wide  range  of
customers,  and  enables  us to pursue  relationships  with  compatible  product
companies for potential joint marketing activities. Our products are sold in gel
and  powder  form in a  variety  of  configurations.  Both  products  are  sold,
physician ordered, and reimbursed (when applicable) by the gram.


                                       10
<PAGE>

Marketing, Sales, and Distribution

The Company  anticipates  building and  supporting a limited sales and marketing
force directed toward  securing key high profile  accounts,  penetrating  select
geographic   markets,   and   supporting   the  efforts  of  our  resellers  and
distributors.  The wound  care  products  market  has a variety  of  overlapping
distribution channels,  with many customers able to procure products in multiple
ways.  With an intended  limited force,  our goal is to market directly to large
accounts and open distribution  channels preferred by those clients,  as well as
marketing through traditional online, offline, trade show and local activities.

Applied Nutritionals is our exclusive supplier of products. Packaging, inventory
management, and shipping activities are currently outsourced to Diamond Contract
Manufacturing, a non-affiliated entity who provides packaging,  warehousing, and
fulfillment services from their Rochester, NY facilities.

R & D

We conduct our research and development activities,  in conjunction with Applied
Nutritionals.  Although  our  efforts are  currently  focused on  marketing  and
selling our current product lines, we anticipate that we will develop derivative
products,  utilizing  the  patented  form of  collagen,  for other  markets  and
applications.

Clinical Studies

Although  no  clinical  studies are  currently  planned,  we intend to conduct a
number of clinical  studies  for the  purposes of  quantifying  the  benefits of
CellerateRX.  We  anticipate  planning  study design and  management  during the
second quarter of 2005.



ITEM 3.  CONTROLS AND PROCEDURES

The President,  who is also the chief executive  officer and the chief financial
officer of the  Company,  has  concluded  based on his  evaluation  as of a date
within  90 days  prior  to the  date of the  filing  of this  Report,  that  the
Company's  disclosure  controls  and  procedures  are  effective  to ensure that
information  required to be  disclosed  by the  Company in the reports  filed or
submitted  by it under the  Securities  Act of 1934,  as amended,  is  recorded,
processed,  summarized  and reported  within the time  periods  specified in the
Securities and Exchange  Commission's  rules and forms, and include controls and
procedures  designed to ensure that information  required to be disclosed by the
Company in such reports is  accumulated  and  communicated  to the  Registrant's
management,  including the president,  as appropriate to allow timely  decisions
regarding required disclosure.

There were no significant changes in the Company's internal controls or in other
factors that could significantly affect these controls subsequent to the date of
such evaluation.












                                       11
<PAGE>

PART II  - OTHER INFORMATION

ITEM 1. Legal Proceedings - None

ITEM 2. Changes in Securities and Use of Proceeds - None

ITEM 3. Defaults Upon Senior Securities - None

ITEM 4. Submission of Matters to a Vote of Security Holders - None

ITEM 5. Other Information - None

ITEM 6. Exhibits

(a) Exhibits
31   Certification pursuant to Rule 13a-14(a)/15d-14(a)
32   Certification  of  Principal  Executive  Officer  and  Principal  Financial
     Officer in  accordance  with 18 U.S.C.  Section 1350, as adopted by Section
     906 of the Sarbanes-Oxley Act of 2002

                                   SIGNATURES

In accordance  with the  requirements  of the Exchange Act, the  registrant  has
caused this report to be signed on its behalf by the undersigned  thereunto duly
authorized.

                                         MB SOFTWARE CORPORATION



Date: May 20, 2005                        /s/ Scott A. Haire
                                         ---------------------------------------
                                         Scott A.  Haire, Chairman of the Board,
                                         Chief Executive Officer and President
                                         (Principal Financial Officer)












                                       12